Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 7OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Myeloid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × magrolimab × Other hematologic neoplasm × Clear all
NCT04435691 2026-04-23

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
110 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

City of Hope Medical Center

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05829434 2024-02-12

MAGROLIC

University of Leipzig

Phase 2 Withdrawn
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡